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1 Introduction 
1.1 Colorectal cancer 
Colorectal cancer is among the most frequently diagnosed cancers worldwide.1,2 In Eu-
rope, it is the second most common cancer in women (205 200 new cases in 2012, 12.7 % 
of all cancer cases) and the third most common cancer in men (241 600 new cases in 
2012, 13.2 % of all cancer cases).2 It caused 12.2 % (214 700 / 1 754 600) of all cancer related 
deaths in 2012.2 In 2009, health-care costs caused by colorectal cancer were estimated 
at € 5.57 billion (11 % of all cancer related health care costs) and productivity losses due 
to morbidity and mortality at € 4.69 billion within the European Union.3 
The incidence of colorectal can-
cer is higher for older and male 
individuals. Median age at the 
time of diagnosis is 66 years for 
males and 69 years for females, 
and median lifetime risk of the 
diagnosis is 4.42 % for males and 
4.06 % for females.4 Table 1 pro-
vides an overview of estab-
lished risk and preventive fac-
tors. However, especially the 
lifestyle factors often occur col-
linearly, hampering independ-
ent analyses.24  
‘Classic’ tumorigenesis of colo-
rectal cancer follows the adenoma-carcinoma-sequence32: Loss of the tumor-suppress-
ing ‘gatekeeping’ APC pathway initiates the development of early adenomas.33-35 Addi-
tional mutations, often activating the KRAS / BRAF pathway, cause further tumor 
growth.32,35,36 The accumulation of additional mutations in other genes or pathways 
(e. g., PIK3CA37,38, TP5339-41, TGF-b / SMAD42-44) results in the progression to adenocar-
cinomas.32,45 
The progression of an adenoma to a carcinoma takes several years45,46. The long asymp-
tomatic course of disease, the high incidence, and the availability of often curative treat-
ment allow efficient screening.47,48 The fecal occult blood test (FOBT)49,50 and the fecal 
immunochemical test (FIT)51 are suitable for first-round screening; positive patients 
should be further examined in colonoscopy.52 Other countries adapted colonoscopy for 
first-round screening.52 Altogether, colonoscopy allows immediate – and potentially 
Factors Risk Reference 
Sociodemographic   
 Older age ­ 4 
 Male sex ­ 4 
Medical   
 Positive family history  ­ 5,6 
 Hereditary syndromes ­ 7,8 
 Inflammatory bowel diseases ­ 9-11 
 Diabetes ­ 12,13 
 ASS ¯ 14,15 
 Postmenopausal hormones ¯ 16,17 
Lifestyle   
 Smoking ­ 18,19 
 Obesity ­ 20,21 
 ­ Consumption of alcohol ­ 22,23 





 ­ Physical activity ¯ 26 
 ­ Consumption of fiber ¯ 27 
 ­ Consumption of calcium ¯ 28-30 
 ­ Consumption of milk ¯ 30,31 
Table 1: Risk factors. Parameters increasing (­) or decreasing (¯) 
the risk to develop colorectal cancer. ASS, acetylsalicylic acid. 
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curative – polypectomy, histopathological evaluation, and reduces colorectal cancer’s 
incidence53 and mortality54. 
Colorectal cancer is diagnosed in screening or in the assessment of symptomatic pa-
tients having e. g. blood in stool, abdominal pain, changed bowel habits, anemia, fatigue, 
or weight loss.55,56 The diagnostic procedures include physical examination, imaging, 
endoscopy, or surgical exploration.52,56,57 Tissue for histopathological reviews is usually 
obtained in endoscopic polypectomy or biopsy and may confirm the diagnosis.56,58,59 
The tumor’s depth of infiltration, its dissemination to regional lymph nodes, and its 
dissemination to distant lymph node regions or other organs determine the TNM-stage 
(Table 2).57,58,60 The TNM-stage enters the UICC / AJCC staging (Table 3)57,61 that helps 
to standardize reports and the selection of optimal treatment59,62 and is associated with 
the prognosis57. 
In patients with malignant polyps that were completely resected and revealed favorable 
histopathology, endoscopic polypectomy is usually considered as curative, and surgery 
is not necessary.63-65 Patients with malignant polyps that were incompletely resected or 
revealed unfavorable histopathology63,64,66, or patients with non-metastasized colorectal 
cancer (stage I – III) in general, should usually undergo surgery in curative intention: 
In colon cancer, complete mesocolic excision includes the resection of the affected 
bowel segment and its mesocolon containing the regional lymph nodes.67,68 For patients 
 Definition 
Tis Carcinoma in situ, Infiltration lamina propria 
T stage  
 T1 Infiltration submucosa 
 T2 Infiltration muscularis propria 
 T3 Infiltration subserosa / pericolic & perirectal tissue 
 T4a Infiltration serosa  
 T4b Infiltration neighboring organs / tissue 
N stage  
 N1a 1 regional lymph node metastasis 
 N1b 2 – 3 regional lymph node metastases 
 N1c Satellite tumor deposits in subserosa / pericolic & 
perirectal tissue w/o regional lymph node metastasis 
 N2a 4 – 6 regional lymph node metastases 
 N2b ³ 7 regional lymph node metastases 
M stage  
 M1a Distant metastasis to 1 organ or distant lymph node 
region w/o peritoneal metastases 
 M1b Distant metastasis to  ³ 1 organ or distant lymph 
node regions w/o peritoneal metastases 
 M1c Peritoneal metastases w or w/o distant metastases to 
other organs or distant lymph node regions 
Table 2: TNM-Classification. Classification of colorectal cancer regard-
ing its depth of infiltration (T stage), the involvement of regional lymph 
nodes (N stage) and the involvement of other organs, distant lymph node 
regions or the peritoneum (M stage). Adapted from Brierley et al.57 Abbre-
viations: w, with; w/o, without. 
 Stage T N M 0 Tis N0 M0 
I T1/T2 N0 M0 
II T3/T4 N0 M0 
 IIA T3 N0 M0 
 IIB T4a N0 M0 
 IIC T4b N0 M0 
III any T N1/N2 M0 
 IIIA T1/T2 N1 M0 
  T1 N2a M0 
 IIIB T3/T4a N1 M0 
  T2/T3 N2a M0 
  T1/T2 N2b M0 
 IIIC T4a N2a M0 
  T3/T4a N2b M0 
  T4b N1/N2 M0 
IV any T any N M1 
 IVA any T any N M1a 
 IVB any T any N M1b 
 IVC any T any N M1c 
Table 3: UICC-Classification. Union 
Internationale Contre le Cancer (UICC) 
/ American Joint Committee on Cancer 
(AJCC) classification of colorectal can-
cer. Adapted from Brierley et al.57 
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with stage II disease, adjuvant chemotherapy is optional and should be considered es-
pecially in high-risk situations.69-72 For patients with stage III disease, adjuvant chemo-
therapy is recommended.60,72,73 
In rectal cancer, selected patients (very early cT1N0, low grade G1 / G2, etc.) may be 
treated by transanal excision or transanal endoscopic microsurgery74-77. Other patients 
should undergo transabdominal surgery with total mesorectal excision (en bloc resec-
tion of mesorectum, mesorectal fat and mesorectal fascia).78,79 Proximal tumors may be 
approachable by lower anterior resection of the rectum, distal tumors can require ab-
dominal perineal resection.77,79,80 Guidelines recommend differently scheduled proto-
cols combining pre- and postoperative chemo- and radiotherapy for patients with stage 
II or III rectal cancer.81,82 
Preferred first-line adjuvant chemotherapy in non-metastatic colorectal cancer is a cy-
totoxic doublet with a fluoropyrimidine and oxaliplatin such as 5-fluoururacil / folinic 
acid and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (XELOX or CAPOX).83-88 
Alternatives are bolus fluorouracil / folinic acid and oxaliplatin (FLOX), and in certain 
situations monotherapy with capecitabine or 5-fluoururacil / folinic acid.89-92 The com-
bination with targeted agents did not improve outcomes in non-metastasized colorectal 
cancer.93-97 
The prognosis of patients with colorectal 
cancer highly depends on the stage: The 5-
year relative survival rate for patients with 
localized cancer is about 90 % but clearly re-
duced for patients with regional-stage dis-
ease (stage II & III, ~ 70 %).4,99,100 However, 
patients with metastatic colorectal cancer 
(stage IV) have the worst prognosis, despite 
significant therapeutic improvements in the 
last decades.101 Table 4 provides detailed 5-
year relative survival rates for colon and rec-
tal cancer. 
1.2 Metastatic colorectal cancer 
Half of all patients with colorectal cancer develop metastases: About 20 % present syn-
chronous metastases at the time of the diagnosis102,103, and 20 – 30 % develop metachro-
nous metastases later in their course of disease104,105. Colorectal cancer metastasizes 
Stage 5-year relative survival rate Colon cancer Rectal cancer 
I 92% 88% 
II   
 IIA 87% 81% 
 IIB 65% 50% 
III   
 IIIA 90% 83% 
 IIIB 72% 72% 
 IIIC 53% 58% 
IV 12% 13% 
Table 4: 5-year relative survival rate by 
stage. 5-year relative survival rate by UICC / 
AJCC stage for colon and rectal cancer according 
to and adapted from cancer.org98. Note that num-
bers are based on a previous version of the TNM 
staging system. 
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most commonly to liver, lungs, peritoneum, and lymph nodes, and less frequently to 
bones, brain, or other organs.102,105,106 
Diagnostic procedures include physical examination, imaging, endoscopy, or surgical 
exploration similarly to non-metastasized colorectal cancer.56,57 Additionally, tissue 
from the primary tumor or metastases107-109 should be genotyped for RAS and 
BRAF,110,111 as patients harboring these mutations do not benefit or benefit less from 
therapy with antibodies targeting the epidermal growth factor receptor (EGFR, cetuxi-
mab and panitumumab).112-116  
The evaluation of distant metastases relies heavily on imaging. Computed tomography 
(CT) is the most commonly used standard (also see 1.3 Computed tomography).117-119 
Magnetic resonance imaging (MRI) should be considered in patients with rectal carci-
noma prior resection120,121 or if the abdominal or pelvic CT is inadequate122,123. PET/CT 
may be considered if the dignity of a suspect structure is unclear, yet crucial for the 
decision whether curative surgery is technically feasible.124,125 
Patients with limited liver or lung metastases may benefit from R0-resection.126-129 If 
R0-resection is technically feasible, primary tumor and metastases can be resected sim-
ultaneously (synchronously) or successively (staged).130-133 In selected patients, alterna-
tively non-resectable metastases can be approached with local therapies such as radio-
embolization134-136, transcatheter arterial chemoembolization (TACE)134,137, or radiofre-
quency ablation (RFA)138,139.140 Chemotherapy should be administered adjuvantly, neo-
adjuvantly or between the resection of the primary tumor and the metastases.141-145  
However, most patients have initially unresectable disease146 and combination-therapy 
is the treatment of choice: In patients with limited disease, downsizing may enable sec-
ondary surgery with curative intention.146-149 In patients with metastases that are un-
likely to become resectable, the treatment intention might be disease control and pre-
venting progression.59,111  
For stage IV disease, preferred combination-therapy includes a chemotherapeutical 
backbone aligned with a targeted agent. The specific treatment strategy and drug selec-
tion depends on the patient’s health status, risk factors, clinical and molecular predic-
tive parameters (e. g., tumor sidedness, mutational status), the treatment goal (e. g., 
downsizing vs disease control), the drug’s side effects and the patient’s prefer-
ences.59,111,150 
Preferred first-line chemotherapies consist of the cytotoxic doublets 5-fluoururacil / fo-
linic acid and irinotecan (FOLFIRI)151-153 or 5-fluoururacil / folinic acid and oxaliplatin 
(FOLFOX)152-154 or capecitabine and oxaliplatin (XELOX or CAPOX)155-157. Alternatives 
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are the combination of 5-fluoururacil / folinic acid, irinotecan and oxaliplatin (FOL-
FOXIRI)158,159 or the less intensive monotherapy with infusional 5-fluoururacil / folinic 
acid160-162 or capecitabine163-165. 
The combination of chemotherapy with antibodies targeting the epidermal growth fac-
tor receptor (EGFR, cetuximab and panitumumab) or the vascular endothelial growth 
factor (VEGF, bevacizumab) increases overall survival and progression-free sur-
vival.112,166-169 EGFR-antibodies are ineffective in presence of RAS mutations, and there-
fore only patients with RAS wild-type gene may receive cetuximab or panitumumab.110-
114 Also, the effectiveness of EGFR-antibodies is smaller in patients with right-sided tu-
mors.170-174 
Combination-therapy prolongs the median overall survival of patients with metastatic 
colorectal cancer up to 30 months in current phase 3 trials and observational regis-
tries.101,111 
1.3 Computed tomography 
Computed tomography (CT) is an established standard for diagnosis and monitoring of 
metastases in colorectal cancer.59,111,117-119,175 Scans should include the chest, the abdo-
men and the pelvis to cover the most common metastatic sites (liver, lungs, peritoneum, 
and lymph nodes).59,111,119,175 
Details of the CT scanner settings and imaging protocols might vary. However, the op-
timal evaluation of the liver and hepatic metastases requires an abdominal scan in portal 
venous phase after applying intravenous iodinated contrast agent.176,177 Furthermore, 
all series should be reconstructed with a slice-thickness of 5 mm or smaller to ensure 
accurate lesion measurements and reliable detection of new metastases.175 
1.4 RECIST 1.1 
The assessment of radiological treatment outcomes of metastatic colorectal cancer pa-
tients relies mostly on RECIST 1.1 (Response Evaluation Criteria in Solid Tumors, ver-
sion 1.1). Based on quantitative and qualitative evaluations, these criteria allow an ob-
jective and reproducible assessment of radiological response and progress.175 
Up to two representative and measurable metastases per organ and up to five metasta-
ses in total are selected as target lesions and their longest diameters are measured. The 
evaluation of lymph nodes is different as their size is measured along the shortest axis 
and only nodes ³ 10 mm are considered as suspect. All measured diameters are summed 
up, its change is calculated relative to the baseline or the ‘nadir’ (smallest sum during 
treatment), and the response is categorized according to the criteria presented in Ta-
ble 5. Altogether, partial response (PR) is significant shrinkage of target lesions ³ 30 % 
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without achieving complete response (CR), and progressive disease (PD) is significant 
growth of target lesions ³ 20 %.175 
All metastases not measured or not measurable are qualitatively evaluated as non-target 
lesions and the tumor response is categorized as described in Table 6.175  
The evaluation of the overall tumor response at a specific time point respects target 
lesions and non-target lesions (Table 7): Altogether, complete response (CR) is the dis-
appearance of all metastases, partial response (PR) is a significant but incomplete re-
sponse, and progressive disease (PD) is a significant growth of any target-lesion, any 
non-target lesion or the appearance of any new metastases. Insignificant size changes 
in patients with target lesions are considered as stable disease (SD), in patients without 
target lesions as non-CR / non-PD.175 
 
Tumor response Target lesions 
CR Complete 
Response 
All TL disappeared and 
all lymph nodes < 10 mm 
PR Partial  
Response 
³ 30 % decrease in diameter 
sum, reference baseline 
SD Stable  
Disease 
Neither CR, PR, nor PD 
PD Progressive 
Disease 
³ 20 % increase in diameter 
sum (min. 5 mm), reference 
nadir 
Table 5: Objective tumor response of target lesions. 
Categories of tumor response of target lesions according 
to RECIST 1.1 (adapted from Eisenhauer et al.175). Abbre-
viations: CR, complete response; PD, progressive dis-
ease; PR, partial response; SD, stable disease; TL, target 
lesions. 
 Tumor response Non-target lesions 
CR Complete 
Response 
All NTL disappeared and all 
lymph nodes < 10 mm and 




Persistence of ³ 1 NTL and / or 
maintenance of tumor marker 
above normal level 
PD Progressive 
Disease 
Unequivocal progression of 
existing NTL 
Table 6: Tumor response of non-target lesions. Cat-
egories of tumor response of non-target lesions accord-
ing to RECIST 1.1 (adapted from Eisenhauer et al.175). 
Abbreviations: CR, complete response; NTL, non-target 
lesions; PD, progressive disease; PR, partial response. 
Target lesions Non-target lesions New lesions Overall response 
CR CR No CR 
— CR No CR 
CR Non-CR / non-PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all evaluated No PR 
— Non-CR / non-PD No Non-CR / non-PD 
SD Non-PD or not all evaluated No SD 
PD Any Yes or no PD 
Any PD Yes or no PD 
Any Any Yes PD 
— PD Yes or no PD 
— Any Yes PD 
    
Not all evaluated Non-PD No NE 
— Not all evaluated  No NE 
Table 7: Overall tumor response at specific time point. Evaluation of the tumor response depending on target 
lesions, non-target lesions and new lesions at a specific time point according to RECIST 1.1 (adapted from Eisenhauer 
et al.175). Abbreviations: CR, complete response; NE, not evaluable; NTL, non-target lesions; PD, progressive disease; 
PR, partial response; SD, stable disease. 
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1.5 Volumetric thresholds according to RECIST 1.1 
RECIST simplifies the measurement of target lesions by focusing on the metastases’ 
longest diameter.175 This reflects the real size change accurately as long as the diame-
ter’s change equals the average change in all directions. 
Improved image postprocessing techniques allow three-dimensional, volumetric tumor 
measurements178,179: In semi-automated volumetry, the lesions’ diameter is manually 
marked, and the software automatically suggests a volumetric segmentation that, if nec-
essary, can be corrected manually (Figure 1). All voxels comprising the metastasis are 
included into the volume of interest (VOI). Thus, the calculated volume might represent 
the size of the whole lesion more accurately than its longest diameter.180 Therefore, and 
as prior studies suggest181, volume changes could correlate better with treatment re-
sponse and outcomes. 
Volumetric segmentation is technically feasible.178 However, the application of volu-
metric criteria is hampered by the lack of thresholds defining response and pro-
gress.182,183 In prior studies, volumetric thresholds equivalent to the established RECIST 
thresholds (- 30 %, + 20 %) were interpolated by using the volume-formula of perfect 
spheres.183-186 This assumes that the change of the measured diameter represents the 
Figure 1: Volumetric segmentation. Semi-automated volumetric segmentation of hepatic metastases of a 62-year-
old female with metastatic colorectal cancer who received FOLFIRI plus bevacizumab. Segmentation was performed 
in the image postprocessing software syngo.via, MM Oncology, Siemens Healthineers, Siemens Healthcare GmbH, 
Erlangen. 
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change in all directions accurately. However, especially in asymmetric or large lesions, 
variations occur. 
The aim of the published study (publication I) was to empirically identify volumetric 
thresholds corresponding to the established diametric RECIST 1.1 thresholds. The au-
thor (F.O.H.) contributed significantly to conception and design of the study, acquisition 
and assembly of the data, statistical analysis and interpretation of the data, and the 
writing of the manuscript.187 
1.6 Radiologically enlarged lymph nodes 
CT is fundamental for diagnosis, treatment planning, and response assessment in pa-
tients with metastatic colorectal cancer. Therefore, most of the patients undergo base-
line CT. Many of the findings (e.g., TNM-stage, number of metastatic sites) influence 
treatment decisions and the patients’ prognosis.57,188 However, baseline CT often also 
reveals findings with unclear prognostic relevance such as the presence of radiologi-
cally enlarged lymph nodes. 
Colorectal cancer tumor cells disseminate through blood and lymphatic vessels.189-193 
The metastatic spread through the lymphovascular system is highly relevant and re-
flected by the metastatic affection of lymph nodes.192,194,195 
Figure 2: Radiologically enlarged lymph node. Radiologically enlarged, paraaortic lymph node of a 43-year-old 
male with metastatic colorectal cancer. Evaluation was performed in the image postprocessing software syngo.via, 
MM Oncology, Siemens Healthineers, Siemens Healthcare GmbH, Erlangen. 
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Lymph node metastases influence the prognosis and the optimal treatment regimen in 
colorectal cancer: For instance, regional lymph node metastases (stage III disease) are 
associated with a reduced overall survival57 and chemotherapy is recommended60,72,73. 
In patients with stage IV disease, regional and distant lymph node metastases are also 
associated with a reduced overall survival.196-198 
The histopathology of radiologically enlarged lymph nodes at baseline often remains 
unclear and its evaluation is limited to morphological properties. In RECIST 1.1, lymph 
nodes with the shortest diameter ³ 10 mm are considered as suspect (Figure 2).175 How-
ever, its prognostic relevance beyond other prognostic parameters remains unclear in 
stage IV disease patients receiving combination-therapy. 
The aim of the published study (publication II) was to determine the prognostic rele-
vance of radiologically enlarged lymph nodes in baseline computed tomography beyond 
established and potential prognostic parameters. The author (F.O.H.) contributed sig-
nificantly to conception and design of the study, acquisition and assembly of the data, 




The aim of the published studies was  
I to determine volumetric thresholds corresponding to the established diametric 
RECIST thresholds defining response and progress of target lesions and 
II to investigate the prognostic relevance of radiologically enlarged lymph nodes in 
baseline computed tomography (CT) of patients with metastatic colorectal cancer 
prior first-line combination-therapy. 
2.2 Materials & Methods 
The published studies are retrospective analyses of the prospective clinical phase 3 trial 
FIRE-3 that included 592 patients with initially unresectable, histologically confirmed 
metastatic colorectal adenocarcinoma (ClinicalTrials.gov, number NCT00433927). FIRE-
3 compared first-line combination-therapy with FOLFIRI aligned with either EGFR-an-
tibody cetuximab or VEGF-antibody bevacizumab.200,201 
In total, 2535 CT of 506 patients were retrospectively evaluated regarding radiological 
response and progress. Therefore, diameters and volumes of 1659 target lesions in liver 
(1224), lungs (282) and lymph nodes (153) were measured in 9226 single semi-automated 
volumetric segmentations. Additionally, non-target lesions were evaluated according to 
RECIST 1.1. Based on the acquired data multiple analyses were performed, among these 
the following: 
I Relative diametric and volumetric size changes of the same hepatic target lesions 
were calculated. Based on this, volumetric thresholds corresponding to the estab-
lished diametric RECIST thresholds were determined with loess-regression. The 
implications on the categorization regarding response and progress were further 
investigated. 
II The prognostic relevance of radiologically enlarged regional and distant lymph 
nodes was investigated in univariable Cox proportional hazard regression and 
Kaplan Meier analysis. The influence of enlarged lymph nodes on survival beyond 
established prognostic parameters was further analyzed in multivariable Cox pro-
portional hazard regression. 
2.3 Results 
I The volumetric threshold indicating response ranged between - 63.6 % and - 65.3 %, 
depending on whether one, the sum of up to two or the sum of up to five target 
lesions was considered. Likewise, the volumetric threshold indicating progress 
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ranged between + 61.7 % and + 64.6 %. To provide a uniform and memorable 
threshold we proposed - 65 % and + 65 % as equivalents to the established RECIST 
thresholds - 30 % and + 20 %. In sensitivity analysis, the deviation from the regres-
sion results only marginally influenced the categorization of cases concordantly 
or discordantly to RECIST. For the sum of up to two metastases, 85.0% of all 
weighted cases categorized as responsive according to volumetry were also re-
sponsive according to RECIST. 91.2 % of all weighted cases without significant 
volumetric size change also had no significant change according to RECIST. 88.3% 
of all weighted cases categorized as progressive according to volumetry were also 
progressive according to RECIST. 
II Of 339 analyzed patients, 178 (52.5 %) had radiologically enlarged lymph nodes at 
baseline CT prior first-line combination-therapy. For these, overall survival (OS) 
was significantly shorter (median OS 21.7 [95 % CI, 18.8 – 24.7] months vs 33.2 
[95 % CI, 28.8 – 38.3] months; HR, 1.61 [95 % CI, 1.23 – 2.09], P < .001). Progression-
free survival (PFS) however was only insignificantly shorter (median PFS 9.9 
[95 % CI, 8.8 – 10.8] months vs 11.1 [95 % CI, 10.1 – 12.3] months; HR, 1.23 [95 % CI, 
0.98 – 1.54], P = .072). Multivariable regression confirmed the negative prognostic 
implication of radiologically enlarged lymph nodes on OS beyond established 
prognostic parameters (HR, 1.37 [95 % CI, 1.02 – 1.83], P = .036). Furthermore, peri-
toneal carcinomatosis, elevated alkaline phosphatase, BRAF mutations and the 
treatment with bevacizumab (instead of cetuximab) were associated with a re-
duced OS. 
2.4 Conclusion 
Volumetric thresholds of - 65 % and + 65 % are corresponding to the established diamet-
ric RECIST thresholds of - 30 % and + 20 % indicating response and progress of target 
lesions. Radiologically enlarged lymph nodes at baseline prior combination-therapy are 






Das Ziel der publizierten Studien war 
I volumetrische Grenzwerte zu bestimmen, die den etablierten, Durchmesser-ba-
sierten Grenzwerten nach RECIST entsprechen, welche das Ansprechen und den 
Progress von „Target Lesions“ definieren, und 
II die prognostische Relevanz von radiologisch vergrößerten Lymphknoten in Base-
line-Computertomographien (CT) von Patienten mit metastasiertem kolorekta-
lem Karzinom vor Erstlinien-Kombinationstherapie zu untersuchen. 
3.2 Material & Methoden 
Die publizierten Studien sind retrospektive Analysen der prospektiven klinischen 
Phase 3 Studie FIRE-3, die 592 Patienten mit initial nicht resektablen, histologisch gesi-
chertem, metastasiertem kolorektalem Adenokarzinom einschloss (ClinicalTrials.gov, 
Nummer NCT00433927). FIRE-3 verglich die Erstlinien-Kombinationstherapie mit FOL-
FIRI kombiniert entweder mit dem EGFR-Antikörper Cetuximab oder mit dem VEGF-
Antikörper Bevacizumab.200,201 
Insgesamt wurden 2535 CT von 506 Patienten retrospektiv hinsichtlich des radiologi-
schen Ansprechens und Progresses ausgewertet. Dazu wurden Durchmesser und Volu-
mina von 1659 „Target Lesions“ in Leber (1224), Lunge (282) und Lymphknoten (153) in 
9226 einzelnen, semi-automatischen, volumetrischen Segmentierungen vermessen. 
Weiterhin wurden „Non-target Lesions“ nach den RECIST 1.1 Kriterien evaluiert. Auf 
Basis der akquirierten Daten erfolgten unter anderem die folgenden Analysen: 
I Die relativen Änderungen der Durchmesser und Volumina der gleichen „Target 
Lesions“ in der Leber wurden berechnet. Basierend darauf wurden volumetrische 
Grenzwerte, die den etablierten Durchmesser-Grenzwerten der RECIST-Kriterien 
entsprechen, mittels loess-Regression bestimmt. Die Auswirkung auf die Katego-
risierung in größenregrediente und größenprogrediente Metastasen wurde weiter 
untersucht. 
II Die prognostische Relevanz radiologisch vergrößerter regionaler und ferner 
Lymphknoten wurde in univariabler Cox proportional hazard Regression und Ka-
plan Meier Analyse analysiert. Der Einfluss auf das Überleben über etablierte 




I Der volumetrische Grenzwert, ab welchem Läsionen als ansprechend kategori-
siert wurden, rangierte zwischen - 63.6 % und - 65.3 %, abhängig davon, ob eine, die 
Summe von bis zu zwei oder die Summe von bis zu fünf Metastasen zur Berech-
nung herangezogen wurde. Der volumetrische Grenzwert, ab welchem Läsionen 
als progressiv kategorisiert wurden, rangierte zwischen + 61.7 % und + 64.6 %. Der 
Einheitlichkeit und Eingängigkeit wegen schlugen wir - 65 % und + 65 % als Äqui-
valente zu den etablierten RECIST-Grenzwerten - 30 % und + 20 % vor. In Sensiti-
vitätsanalysen beeinflusste die Abweichung von den Ergebnissen der Regressio-
nen nur minimal, ob die Kategorisierung mit RECIST übereinstimmte oder davon 
abwich. In der Untersuchung der Summe von bis zu zwei Metastasen, waren 85.0 % 
der gewichteten, nach Volumetrie signifikant größenregredienten Fälle auch nach 
den RECIST größenregredient. 91.2 % der gewichteten Fälle ohne signifikante vo-
lumetrische Größenänderung hatten auch nach RECIST keine signifikante Grö-
ßenänderung. Ebenso waren 88.3 % der gewichteten, nach Volumetrie größenpro-
gredienten Fälle nach RECIST ebenfalls größenprogredient. 
II Von 339 analysierten Patienten hatten 178 (52.5 %) radiologisch vergrößerte 
Lymphknoten in der Baseline-CT vor Erstlinien-Kombinationstherapie. Ihr Ge-
samtüberleben (OS) war signifikant kürzer (medianes OS 21.7 [95 % CI, 18.8 – 24.7] 
Monate vs 33.2 [95 % CI, 28.8 – 38.3] Monate; HR, 1.61 [95 % CI, 1.23 – 2.09], P < .001). 
Das progressionsfreie Überleben (PFS) hingegen war nur insignifikant kürzer 
(medianes PFS 9.9 [95 % CI, 8.8 – 10.8] Monate vs 11.1 [95 % CI, 10.1 – 12.3] Monate; 
HR, 1.23 [95 % CI, 0.98 – 1.54], P = .072). Die multivariable Regression bestätigte den 
negativen prognostischen Einfluss radiologisch vergrößerter Lymphknoten auf 
das Gesamtüberleben über etablierte prognostische Parameter hinaus (HR, 1.37 
[95 % CI, 1.02 – 1.83], P = .036). Weiterhin waren Peritonealkarzinose, erhöhte alka-
lische Phosphatase, Mutation des BRAF-Gens sowie die Behandlung mit Bevaci-
zumab (anstelle von Cetuximab) mit kürzerem Gesamtüberleben assoziiert. 
3.4 Schlussfolgerung 
Volumetrische Grenzwerte von - 65 % und + 65 % entsprachen den etablierten Durch-
messer-basierten Grenzwerten der RECIST-Kriterien von - 30 % und + 20 %, die das An-
sprechen und den Progress von „Target Lesions“ definieren. Radiologisch vergrößerte 
Lymphknoten in der Baseline-Computertomographie vor Kombinationstherapie sind 
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